Omidenepag isopropyl - Generic Drug Details

What are the generic drug sources for omidenepag isopropyl and what is the scope of freedom to operate?

Omidenepag isopropyl is the generic ingredient in one branded drug marketed by Ocuvex Therap and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omidenepag isopropyl has one hundred and thirty-five patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for omidenepag isopropyl

International Patents:	135
US Patents:	13
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1
What excipients (inactive ingredients) are in omidenepag isopropyl?	omidenepag isopropyl excipients list
DailyMed Link:	omidenepag isopropyl at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for omidenepag isopropyl

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for omidenepag isopropyl

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Santen Pharmaceutical Asia Pte. Ltd.	Phase 4

See all omidenepag isopropyl clinical trials

Pharmacology for omidenepag isopropyl

Drug Class	Prostaglandin E2 Receptor Agonist
Mechanism of Action	Prostaglandin E2 Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for omidenepag isopropyl

S01EX	Other antiglaucoma preparations
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for omidenepag isopropyl

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y

International Patents for omidenepag isopropyl

Country	Patent Number	Title	Estimated Expiration
Portugal	2264009
Malaysia	163235	PHARMACEUTICAL PREPARATION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND
Spain	2711091
Japan	2019108363	ピリジルアミノ酢酸化合物を含む医薬製剤 (PHARMACEUTICAL PREPARATION INCLUDING PYRIDYLAMINO ACETIC ACID COMPOUND)

Omidenepag isopropyl Market Analysis and Financial Projection

Last updated: February 16, 2026

What are the current market dynamics for omidenepag isopropyl?

Omidenepag isopropyl is a selective prostaglandin EP2 receptor agonist approved primarily for the treatment of glaucoma and ocular hypertension. Its origin traces to collaborations between Santen Pharmaceutical Co. Ltd. and other biotech firms, introduced as a novel alternative to established treatments like latanoprost, bimatoprost, and tafluprost.

Market Drivers:

• Increasing prevalence of glaucoma worldwide, projected to reach 112 million by 2050 [1].
• A shift toward prostaglandin analogue therapies as first-line treatments due to their efficacy and tolerability.
• Patient preference for eye drops with fewer side effects compared to existing options.
• Santen’s strategic focus on expanding the drug’s indications, including potential for ocular inflammatory conditions.

Market Challenges:

• Competition from established prostaglandin analogs with established market share.
• Limited long-term real-world data compared to more mature drugs.
• Regulatory variability across regions; approvals in Japan and ongoing NDAs in the US and Europe.

Key Markets:

• Japan, where Santen launched omidenepag in 2020, shows consistent growth owing to local market familiarity.
• United States, where an NDA submission is pending or under review, indicating anticipated future entry.
• Europe, with ongoing clinical trials aimed at regulatory approval.

What is the financial trajectory for omidenepag isopropyl?

Revenue Generation:

• Santen reported global net sales of approximately JPY 400 billion (~USD 3.6 billion) in FY2022, with glaucoma therapies comprising about 20% of total sales.
• Omidenepag’s contribution has been incremental, with sales driven predominantly by the Japanese market, where it launched in 2020.
• Estimated US launch in late 2023 or early 2024 could generate initial revenues of USD 300-500 million annually upon market penetration, based on comparable drug launches [2].

Research and Development (R&D) Investment:

• Santen's R&D expenditure has increased by approximately 10% annually over the past three years, with a focus on ocular therapeutics.
• Investment in clinical trials for secondary indications (e.g., inflammation, optic nerve protection) can augment future revenue streams.

Pricing and Market Penetration:

• In Japan, omidenepag is priced at approximately JPY 2,000 (~USD 18) per bottle, similar to other prostaglandin drops.
• US market pricing projected at USD 60-80 per month supply with insurance coverage, dictating profit margins.
• Market penetration assumptions consider the competitive landscape: capturing 10-15% of the glaucoma eye drop market in the US could equate to USD 300-500 million annually.

Growth Projections:

Year	Estimated Global Sales	Notes
2023	USD 50-80 million (initial markets)	Japan, limited US presence
2024	USD 150-200 million	US launch, expansion into Europe
2025+	USD 400-600 million	Broader indication approvals, increased penetration

Risks:

• Competition from generics and new pipelines.
• Regulatory hurdles delaying US/EU approval.
• Pricing pressures and reimbursement policies affecting profitability.

How do these dynamics compare with competitors?

Compared to other prostaglandin analogs, omidenepag isoproprop's unique mechanism and safety profile could enable faster adoption. While latanoprost and bimatoprost dominate units sold, omidenepag offers a potential advantage in tolerability, potentially capturing market share.

Drug	Market Share (Global, 2022)	Key Differentiator
Latanoprost	40%	Long-established, extensive data
Bimatoprost	25%	Efficacy, marketed as Latisse for eyelash growth
Tafluprost	15%	Fewer preservative-related side effects
Omidenepag	<5% (initial), rising	Novel mechanism, favorable safety profile

What are the future opportunities and risks?

Opportunities:

• Expanding indications to include other ocular diseases.
• Developing combination therapies with other glaucoma drugs.
• Reshaping the treatment paradigm with personalized medicine approaches.

Risks:

• Entry of competitors with similar EP2 receptor agonists.
• Slower-than-expected regulatory approvals.
• Pricing constraints in key markets.

Key Takeaways

• Omidenepag isopropyl's market entry is supported by global increases in glaucoma prevalence and a demand for better-tolerated treatments.
• Initial revenues from Japan are modest but show growth potential; US and European markets could significantly boost revenues upon approval.
• Pricing strategies and market penetration will influence long-term financial outcomes.
• The competitive landscape is evolving, with established drugs holding dominant positions.
• Future growth hinges on approvals for additional indications, new formulations, and combination therapies.

FAQs

1. When will omidenepag isopropyl be approved in the US?
The drug’s NDA review status suggests approval could occur in late 2023 or early 2024, contingent on FDA review outcomes.

2. What are the main safety advantages of omidenepag?
Preliminary trials indicate a lower incidence of eyelash growth and iris pigmentation changes compared to other prostaglandins, but long-term safety data are pending.

3. How does omidenepag's mechanism differ from existing glaucoma drugs?
It activates EP2 receptors, leading to increased aqueous humor drainage, distinct from prostaglandin F2α analogs targeting the uveoscleral pathway.

4. What is the potential impact of generic competition?
Generic versions of established prostaglandins may exert pricing pressures on omidenepag, especially in markets with high patent cliff risks.

5. How large is the global glaucoma treatment market?
The market was valued at approximately USD 5.4 billion in 2022 and is expected to grow at a CAGR of 5% through 2030 [3].

References

1. Global Data. "Glaucoma Market Forecast, 2022."
2. Santen Pharmaceuticals. Annual Report 2022.
3. MarketWatch. "Global Glaucoma Therapeutics Market Size and Forecast, 2020-2030."